Timothy Law: GLP-1 Drugs Changed the Paradigm in Weight Loss | AHIP 2024
In an interview, Timothy Law, DO, MBA, chief medical officer of Highmark, talks about how GLP-1 agonist drugs like Wegovy and Zepbound are changing the paradigm for weight loss.
Drugs like Wegovy and Zepbound are not a panacea for those people looking for a quick fix, Timothy Law, DO, MBA, chief medical officer of Highmark Inc., said in an interview with Managed Healthcare Executive before the annual AHIP meeting in Las Vegas. Law — along with panelists Melanie R. Jay, M.D., director of NYU Langone Comprehensive Program on Obesity Research, and Amy Meister, D.O., chief medical officer of WeightWatchers, is speaking about how GLP-1 therapies are changing how the healthcare industry views prevention and treatment.
Highmark is an independent licensee of the Blue Cross Blue Shield Association about 7 million members in Pennsylvania, Delaware, New York and West Virginia.
Here Law talks about what GLP-1 agonist drugs like Wegovy (semaglutide) and Zepbound (tirzepatide) can do and the important of lifestyle management
